Phio Pharmaceuticals Corp. (PHIO) - Q2 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2025. Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company developing immuno-oncology therapeutics using its proprietary INTASYL self-delivering siRNA technology. The company operates as a single segment focused on clinical development, with no product revenues to date. As of August 12, 2025, there were 5,726,750 shares of common stock outstanding.
Key Financial Metrics
| Metric | Q2 2025 (3 Months) | YTD 2025 (6 Months) | Balance Sheet (June 30, 2025) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(2,166,000) | $(3,935,000) | N/A |
| Operating Expenses | $2,309,000 | $4,181,000 | N/A |
| Cash and Equivalents | N/A | N/A | $10,775,000 |
| Total Assets | N/A | N/A | $11,301,000 |
| Total Liabilities | N/A | N/A | $1,206,000 |
| Stockholders' Equity | N/A | N/A | $10,095,000 |
| Cash Flow from Operations | N/A | $(3,815,000) | N/A |
| Cash Flow from Financing | N/A | $9,213,000 | N/A |
Note: All amounts in thousands unless otherwise specified. The company has no debt obligations listed on the balance sheet.
Material Changes vs. Prior Period
- Net Loss: Net loss for the three months ended June 30, 2025, increased to $2.17 million from $1.85 million in the same period in 2024. For the six months, the net loss decreased slightly to $3.94 million from $4.00 million.
- Operating Expenses: Total operating expenses increased by $395,000 (21%) for the quarter compared to 2024. Research and Development (R&D) expenses rose 24% to $1.07 million, driven by higher patient enrollment pass-through costs and consultant fees. General and Administrative (G&A) expenses increased 18% to $1.24 million, primarily due to new hire salaries.
- Liquidity: Cash and cash equivalents increased significantly from $5.38 million at December 31, 2024, to $10.78 million at June 30, 2025. This increase was driven by net proceeds of approximately $9.2 million from financing activities, including the issuance of common stock and the exercise of warrants.
- Capital Structure: The company completed multiple registered direct offerings and private placements in late 2024 and early 2025, significantly increasing the number of outstanding shares and warrants.
Outlook, Risks, and Unusual Items
- Clinical Progress: The Phase 1b clinical trial for lead candidate PH-762 (targeting PD-1) is ongoing. As of June 25, 2025, the Safety Monitoring Committee recommended dose escalation to the fifth cohort. Enrollment is expected to complete in Q3 2025. Early data showed pathologic complete responses in 5 of 13 patients with cutaneous squamous cell carcinoma.
- Going Concern: The filing explicitly states that the company's recurring losses and negative cash flows raise substantial doubt about its ability to continue as a going concern. Management expects to fund operations into Q2 2026 based on current cash, but additional capital will be required.
- Subsequent Financing: In July 2025, the company completed a financing raising approximately $2.2 million through the exercise of existing warrants at reduced prices and the issuance of new Series J and K warrants.
- Collaboration Termination: The company terminated its clinical co-development agreement with AgonOx in May 2024. All obligations were settled by March 2025.
- Executive Departure: Robert Infarinato, formerly CFO and VP of Strategic Development, terminated his employment on July 31, 2025. A separation agreement was executed providing for severance and equity vesting.
- Risk Factors: Key risks include the unproven nature of the INTASYL technology, potential delays in clinical trials, dependence on third-party manufacturers, and the risk of delisting from Nasdaq if stockholders' equity or minimum bid price requirements are not met.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the management estimate that current cash ($10.8M) will fund operations into Q2 2026, given the burn rate of ~$3.8M per six months.
- Dilution Impact: Review the terms of the July 2025 financing and the large number of outstanding warrants (6.6 million shares) to assess potential future dilution.
- Clinical Data: Monitor the release of full data from the PH-762 Phase 1b trial, specifically the response rates in the higher dose cohorts.
- Nasdaq Compliance: Confirm continued compliance with Nasdaq listing rules regarding minimum stockholders' equity ($2.5M) and minimum bid price ($1.00), especially given the company's history of reverse stock splits.
- Management Stability: Assess the impact of the recent CFO departure and the appointment of new financial leadership on future capital raising efforts.